Aduro biotech, inc. (ADRO)
Balance Sheet / TTM
Mar'20Dec'19Sep'19Jun'19Mar'19Dec'18Sep'18Jun'18Mar'18Dec'17Sep'17Jun'17Mar'17Dec'16Sep'16Jun'16Mar'16Dec'15Sep'15Jun'15Mar'15Dec'14
Assets
Current assets:
Cash and cash equivalents

94,381

59,624

53,605

79,561

113,114

126,310

120,751

114,401

100,279

157,614

159,040

183,815

107,068

74,932

97,983

105,938

120,133

150,456

180,991

465,867

132,984

119,456

Marketable securities

108,539

153,978

178,182

172,072

153,794

140,129

145,043

174,711

207,029

168,489

186,467

193,428

246,893

272,500

271,985

287,415

281,848

265,198

-

-

-

-

Short-term marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

264,957

-

-

-

Accounts receivable

1,053

342

222

1,363

707

12,037

-

1,042

702

989

1,348

3,434

1,048

1,138

1,056

1,384

1,867

4,846

3,147

1,214

531

3,153

Income tax receivable

5,665

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Income tax receivable

-

-

-

-

-

-

17,841

17,495

17,495

17,495

12,509

-

-

-

-

-

-

-

-

-

-

-

Prepaid expenses and other current assets

2,676

3,958

3,805

3,779

4,839

4,500

4,128

4,606

5,309

5,544

4,597

4,278

5,911

6,194

7,199

13,078

9,723

4,004

3,494

2,515

3,446

2,612

Total current assets

212,314

217,902

235,814

256,775

272,454

282,976

287,763

312,255

330,814

350,131

363,961

384,955

360,920

354,764

378,223

407,815

413,571

424,504

452,589

469,596

136,961

125,221

Marketable securities

3,011

-

3,593

-

-

11,434

12,840

16,783

20,541

23,614

27,999

-

1,992

14,474

17,179

3,566

6,479

15,391

-

-

-

-

Long-term marketable securities

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

2,464

-

-

-

Property and equipment, net

22,492

24,688

25,534

26,177

28,169

29,157

29,806

30,331

30,168

31,085

28,280

26,360

26,443

26,384

25,931

17,227

5,548

3,986

2,454

2,122

1,376

1,053

Operating lease right-of-use assets

20,722

21,110

21,346

21,609

21,828

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Goodwill

8,010

8,167

7,949

8,277

8,168

8,334

8,449

8,506

8,972

8,723

8,602

8,318

7,779

7,658

8,164

8,572

8,766

8,469

-

-

-

0

Intangible assets, net

18,478

18,978

18,608

24,684

24,499

25,135

29,698

30,044

31,843

31,107

30,822

29,946

28,135

27,827

29,805

29,659

30,471

29,400

-

-

-

-

Restricted cash

468

468

468

468

468

468

468

468

468

468

468

468

-

468

-

-

-

-

-

-

-

-

Restricted cash

-

-

-

-

-

-

-

-

-

-

-

-

468

-

468

468

-

-

-

-

-

-

Deferred tax assets

-

-

-

-

-

-

-

-

-

-

4,283

5,047

6,319

6,319

-

-

-

-

-

-

-

-

Other assets

-

-

-

-

-

-

-

-

-

-

716

8,465

3,438

717

7,216

2,747

3,177

75

347

833

428

188

Total assets

285,495

291,313

313,312

337,990

355,586

357,504

369,024

398,387

422,806

445,128

465,131

463,559

435,494

438,611

466,986

470,054

468,012

481,825

457,854

472,551

138,765

126,462

Liabilities and Stockholders’ Equity
Current liabilities:
Accounts payable

752

414

1,643

1,000

1,573

1,457

780

992

1,847

1,150

1,479

2,813

2,564

2,206

1,908

2,398

5,226

5,086

4,413

3,961

3,680

5,030

Accrued clinical trial and manufacturing expenses

4,823

4,253

4,012

3,894

2,742

2,542

3,760

4,110

3,876

5,898

6,616

4,048

4,846

4,777

7,283

13,878

10,614

5,522

4,886

4,181

4,703

3,350

Accrued expenses and other liabilities

10,116

8,181

9,125

7,881

8,049

10,518

8,601

8,801

8,569

12,601

11,249

7,073

6,428

8,597

9,678

8,459

10,207

5,412

4,069

5,967

5,394

2,408

Operating lease liabilities

1,765

1,803

1,700

1,630

1,539

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Contingent consideration

-

-

-

-

-

-

-

6,799

7,172

6,829

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

5,808

6,950

16,000

16,000

16,000

16,000

17,744

17,613

-

14,923

-

-

-

-

-

-

-

-

-

-

-

-

Deferred revenue

-

-

-

-

-

-

-

-

14,882

-

14,945

14,945

14,983

15,052

15,164

15,171

15,046

15,046

19,732

17,754

26,947

33,427

Total current liabilities

23,264

21,601

32,480

30,405

29,903

30,517

30,885

38,315

36,346

41,401

34,289

28,879

28,821

30,632

34,033

39,906

41,093

31,066

33,100

31,863

40,724

44,215

Deferred rent

-

-

-

-

-

11,063

10,843

10,955

11,109

9,991

8,471

7,778

7,262

6,786

5,937

2,952

932

-

56

-

-

-

Contingent consideration

1,972

1,051

975

1,015

978

998

941

947

999

759

6,250

6,044

4,095

4,032

3,542

3,508

3,594

3,750

-

-

-

-

Deferred revenue

165,208

166,963

161,203

165,908

169,497

172,671

161,591

164,586

-

148,148

-

-

-

-

-

-

-

-

-

-

-

-

Deferred consideration from Novartis collaboration (Note 5)

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

200,000

-

-

Deferred revenue

-

-

-

-

-

-

-

-

169,857

-

151,852

155,556

159,259

162,963

166,667

170,370

174,276

178,037

181,481

-

-

2,592

Deferred tax liabilities

3,459

3,527

3,522

5,992

5,948

6,104

6,237

6,319

6,704

6,538

6,481

6,307

5,931

5,869

6,868

7,379

7,840

7,350

-

-

-

-

Operating lease liabilities

31,258

31,636

32,120

32,599

33,030

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

Other long-term liabilities

753

940

966

1,021

841

840

832

831

832

818

1,374

1,255

1,109

1,109

-

-

-

-

-

-

-

-

Warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

1,096

-

Common stock warrant liability

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

9,235

-

Total liabilities

225,914

225,718

231,266

236,940

240,197

222,193

211,329

221,953

225,847

207,655

208,717

205,819

206,477

211,391

217,047

224,115

227,735

220,203

214,637

231,863

51,055

47,796

Commitments and contingencies (Note 7)

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

0

0

Convertible preferred stock; $0.0001 par value, zero and 69,716,345 shares authorized at December 31, 2015 and 2014; zero and 69,608,339 shares issued and outstanding at December 31, 2015 and 2014

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

-

164,964

139,963

Stockholders’ equity:
Preferred stock, $0.0001 par value; 10,000,000 shares authorized; no shares issued and outstanding at March 31, 2020 and December 31, 2019

-

-

-

-

-

-

0

0

0

-

0

0

0

0

0

0

0

0

0

0

-

0

Common stock, $0.0001 par value; 300,000,000 shares authorized; 80,837,093 and 80,735,688 shares issued and outstanding at March 31, 2020 and December 31, 2019

8

8

8

8

8

8

8

8

8

8

8

7

7

7

7

6

6

6

6

6

-

-

Additional paid-in capital

554,192

552,077

549,705

546,537

542,849

538,895

534,632

530,312

524,997

519,435

512,436

490,336

444,165

420,897

411,516

372,924

369,009

362,807

347,088

345,201

1,005

346

Accumulated other comprehensive (loss) income

-140

414

-178

1,042

491

940

1,267

1,179

2,621

1,893

1,701

608

-1,343

-1,684

850

392

941

-339

75

-

-

-

Accumulated deficit

-494,479

-486,904

-467,489

-446,537

-427,959

-404,532

-378,212

-355,065

-330,667

-283,863

-257,731

-233,211

-213,812

-192,000

-162,434

-127,383

-129,679

-100,852

-103,952

-104,519

-78,259

-61,643

Total stockholders’ equity

59,581

65,595

82,046

101,050

115,389

135,311

157,695

176,434

196,959

237,473

256,414

257,740

229,017

227,220

249,939

245,939

240,277

261,622

243,217

240,688

-77,254

-61,297

Total liabilities and stockholders’ equity

285,495

291,313

313,312

337,990

355,586

357,504

369,024

398,387

422,806

445,128

465,131

463,559

435,494

438,611

466,986

470,054

468,012

481,825

457,854

472,551

138,765

126,462